Merck & Co. Inc. (NYSE:MRK) is one of the best low risk stocks to buy in 2026. On May 18, Merck announced that its pivotal ...
Start a conversation with TipRanks’ trusted, data-backed investment intelligence Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds Merck & ...
Merck (NYSE:MRK) reported positive Phase 3 results for its antibody drug conjugate sacituzumab tirumotecan in advanced ...
All of them could be "forever" holdings, but the coming decade could prove surprisingly fruitful for each of these outfits.
AstraZeneca (AZN), and AbbVie (ABBV) are among the winners of positive drug recommendations in the EU this week. Read more ...
Merck & Co., Inc. (NYSE:MRK) is a global health care company working to deliver innovative health solutions through our ...
Merck reported first-quarter results that topped estimates on strong demand for its cancer immunotherapy Keytruda and some newer products. The pharmaceutical giant also narrowed its 2026 sales ...
By Siddhi Mahatole May 21 (Reuters) - Sichuan Kelun-Biotech Biopharmaceutical said on Thursday its experimental treatment ...
New awareness initiative encourages people to look beyond blood pressure and better understand their heart health ...
EU CHMP recommends approval of Merck’s Keytruda plus Padcev as perioperative treatment for adults with cisplatin-ineligible resectable muscle-invasive bladder cancer: Rahway, Ne ...
Zacks Investment Research on MSN
Merck & Co., Inc. (MRK) is attracting investor attention: Here is what you should know
Merck (MRK) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over the ...
The trial assesses Precem-TcT efficacy and safety alone or with bevacizumab in mCRC patients after previous therapies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results